Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-6231
- Development stage
- Phase 1
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
mRNA-6231 is an investigational, lipid nanoparticle–encapsulated, mRNA-based therapy developed by Moderna. It encodes a modified human interleukin 2 (IL-2) mutein fused to human serum albumin (HSA-IL2m), designed for subcutaneous administration. The drug’s mechanism of action centers on the preferential expansion of regulatory T cells (Tregs) through the expression of this engineered IL-2 protein. By selectively expanding Tregs, mRNA‑6231 aimed to restore immune homeostasis and was being developed for autoimmune diseases. The program reached Phase 1 clinical trials but was discontinued following early clinical data and changes in the competitive landscape[1][3][5][8].
02
Targets
IL2RB (IL-2 receptor beta chain)
Beyond the preview
Go deeper on mRNA-6231.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-6231.